<?xml version="1.0" encoding="UTF-8"?>
<p>Brazil, a middle‐income country, has been providing universal access to antiretroviral therapy for HIV since 1996, driven by strong political will, multisectoral mobilisation and use of Trade Related Aspects of Intellectual Property Rights (TRIPS) flexibilities, and civil society engagement.
 <xref rid="liv14222-bib-0067" ref-type="ref">67</xref> It has championed the cause of viral hepatitis and advocated for an intensified global response for many years. Learning from its successes in reversing the trend of the HIV epidemic, Brazil established a national hepatitis programme informed by up‐to‐date estimates of disease prevalence, international guidelines and cost‐effectiveness in the Brazilian Unified Health System.
 <xref rid="liv14222-bib-0057" ref-type="ref">57</xref> Brazil invested in universal hepatitis B vaccination, increased capacity for hepatitis C testing in HIV services, expanded its laboratory network and set up a referral system for hepatitis patients. To reach the target population, the Ministry of Health conducted new public awareness and diagnosis campaigns using a variety of media with endorsement from civil society and the scientific community.
 <xref rid="liv14222-bib-0057" ref-type="ref">57</xref>
</p>
